Independent Peptide Testing and Batch Verification | Veyvora
Overview
Independent peptide testing verifies a research-peptide batch’s identity, purity and concentration through analytical methods, including high-performance liquid chromatography (HPLC), mass spectrometry and endotoxin assay, conducted outside the supplier’s own sales process, with results recorded on a batch-specific certificate of analysis (CoA) that names the exact lot number tested. Veyvora’s published verification specification states that each research-peptide batch is checked independently by a third-party laboratory (Asterion Analytics) and again by Veyvora’s own internal testing, using HPLC, mass spectrometry and endotoxin assay, with the batch number used to connect results to the material supplied (Veyvora, 2026).
The ICH Q2(R2) guideline, legally effective June 2024, defines the validation framework that governs how such analytical procedures must demonstrate specificity, accuracy and precision before their results can be considered fit for purpose. ICH Q6B, the harmonised standard for biotechnological and peptide products, specifies peptide mapping by HPLC, amino acid analysis and mass spectrometry as the accepted techniques for confirming lot-release identity. Together, these frameworks set the methodological baseline against which any independent peptide testing programme should be assessed.
By the end of this page you will understand: what CoA fields are required to match a result to a specific batch; which analytical attributes validated testing can and cannot establish; and how Veyvora’s two-stage verification workflow — third-party assay plus internal testing — maps onto ICH Q2(R2) and ICH Q6B requirements.
Key Takeaways
- Independent peptide testing establishes four batch-specific attributes: molecular identity, purity percentage, impurity profile and assay (content), each bounded by the validated method and acceptance criteria on the CoA.
- A CoA is valid evidence only for the batch whose lot number it carries; a mismatch between the vial and the document means the certificate cannot be used for that material.
- HPLC purity, mass spectrometry identity and endotoxin readings each measure a distinct attribute; no single result substitutes for the others.
- Testing characterises analytical quality only, it does not establish clinical safety, efficacy or suitability for human administration.
Analytical Purpose of Independent Peptide Testing
The analytical purpose of independent peptide testing is precise: to establish whether a specific batch meets defined quality attributes before it enters a laboratory workflow. ICH Q6B identifies peptide mapping by HPLC, amino acid analysis and mass spectrometry as the accepted techniques for confirming lot-release identity. ICH Q2(R2), legally effective June 2024, sets the validation framework that governs how each of those procedures must demonstrate specificity, accuracy and precision before its results are considered fit for purpose.
Each research-peptide batch Veyvora supplies is checked independently by a third-party laboratory and again by Veyvora’s own internal testing, using HPLC, mass spectrometry and endotoxin assay, with the batch number connecting results to the material supplied (Veyvora, 2026). Understanding what HPLC purity does and does not prove is the necessary next step before interpreting any CoA figure.
Fields, Outputs and Workflow Steps
A documented independent peptide testing workflow moves through four sequential stages: sample receipt and identification, validated analytical measurement, results review against acceptance criteria, and issue of a batch-specific CoA.
Stage-by-Stage Workflow
| Stage | Action | Key output |
|---|---|---|
| 1. Sample receipt | Assign unique lot/batch identifier; record product name, vial size and receipt date | Sample log entry linked to batch number |
| 2. Analytical measurement | Run HPLC for purity percentage; LC-MS (liquid chromatography–mass spectrometry) for molecular identity (expected vs found molecular weight); endotoxin assay | Raw chromatogram, mass spectrum, endotoxin reading |
| 3. Results review | Compare each result against pre-defined acceptance criteria per ICH Q2(R2) | Pass/fail conclusion per parameter |
| 4. CoA issue | Record all results, acceptance criteria, test date and authorised signatory on a batch-specific document | Signed, lot-numbered CoA |
ICH Q6B identifies peptide mapping by HPLC, amino acid analysis and mass spectrometry as the accepted techniques for structure confirmation and impurity profiling at lot release. ICH Q2(R2), legally effective June 2024, requires each analytical procedure to demonstrate specificity, accuracy and precision across the reportable range before its results are considered fit for purpose.
A third-party laboratory and Veyvora’s own internal testing each check every batch, with the batch number connecting results to the material supplied (Veyvora, 2026). The CoA fields that result from this process, purity percentage, identity verdict, endotoxin reading, test date and lot number, are the minimum a laboratory researcher should verify before a batch enters any in-vitro workflow. For specialist terms such as assay, identity and endotoxin, see the research-peptide glossary. Cold-chain integrity is a separate question not answered by any CoA field; consult the storage and stability guidance for that assessment.
What the Evidence Can Establish
Validated independent peptide testing can establish four batch-specific analytical attributes: molecular identity, purity percentage, impurity profile and assay (content). Each attribute is bounded by the methods and acceptance criteria documented in the CoA; results are valid only for the conditions under which testing was performed.
Identity is confirmed when mass spectrometry returns a found molecular weight that matches the expected value for the target sequence. Purity is expressed as the percentage of total detected material represented by the target HPLC peak, a figure that depends on detector wavelength, column chemistry and the range of impurities the method can resolve, as covered in the dedicated HPLC purity method guide. Impurity profiling characterises related substances detected above the reporting threshold; ICH Q6B identifies reversed-phase HPLC (RP-HPLC) and peptide mapping as accepted techniques for this purpose at lot release. Assay (content) quantifies the amount of target peptide present relative to a reference standard, confirming that the stated concentration falls within the acceptance range defined in the specification.
An HPLC purity result measures the proportion of detected material represented by the target peak. By itself, it does not prove molecular identity, concentration accuracy, sterility or cold-chain integrity (Veyvora, 2026). Researchers assessing batches from Veyvora’s research-peptide catalogue should verify that the CoA reports all four attributes, not purity alone, before a lot enters any in-vitro workflow.
What It Cannot Establish
Independent peptide testing characterises analytical quality attributes, specifically identity, purity, impurity profile and assay, but does not establish clinical safety, efficacy or suitability for human administration. ICH Q2(R2), legally effective June 2024, explicitly limits its scope to validating analytical procedures for release and stability testing, addressing data quality rather than biological performance. ICH Q6B similarly focuses on specifications and structural confirmation for lot release, without making claims about clinical outcomes.
A CoA attests that a batch met defined acceptance criteria at the time of testing under the conditions described. It does not confirm long-term stability under untested storage conditions, performance in complex biological matrices, or suitability for formulations outside those studied, unless separate validated stability or compatibility studies have been performed and reported. Questions about cold-chain integrity and degradation risk fall outside the CoA’s scope entirely; Veyvora’s storage and stability guidance addresses those variables separately.
Where endotoxin testing is performed, the result establishes a measured endotoxin level against a defined limit. It does not constitute a sterility assurance claim unless a validated sterility test has also been conducted and reported under appropriate conditions. Each analytical result should be treated as evidence only for the attribute the validated method was designed to measure.
How to Match the Result to a Batch
Matching an analytical result to a specific batch requires consistent use of a unique lot number that appears on both the physical container and the CoA. Before a batch enters any laboratory workflow, compare the lot number printed on the vial or pen directly against the lot number recorded on the CoA, a mismatch means the document cannot be treated as evidence for that material.
Beyond the lot number, four additional fields should align: product name, stated strength or concentration, vial size, and the test date on the CoA. EU-harmonised batch certificate requirements specify that batch number, date of manufacture, expiry date, manufacturing sites and analytical results must all appear on the release document. NHS Specialist Pharmacy Service (SPS) guidance (2024) adds that each CoA must state acceptance criteria alongside the results for that specific batch, signed by the Head of Quality or delegate; a certificate that omits acceptance criteria should be challenged before the material is used.
Where a supplier provides a QR code or a searchable lot-number field, entering the identifier from the physical container is the most direct way to confirm that the retrieved record corresponds to the correct batch rather than a generic product-level document. To act on a specific batch now, use verify your batch to enter the lot number from the vial or pen and retrieve the corresponding CoA. Readers unfamiliar with terms such as assay, identity or endotoxin as they appear on a CoA can consult the research-peptide glossary before reviewing batch documentation.
Related Testing Guides
Three dedicated guides extend the verification process covered on this page. Researchers who need to understand what an HPLC purity figure does and does not prove can consult what HPLC purity does and does not prove, which covers method scope, peak-area interpretation and the limits of chromatographic evidence. Those ready to act on a specific batch can use verify your batch to enter the lot number from the vial or pen and retrieve the corresponding CoA.
ICH Q2(R2), effective June 2024, and ICH Q6B remain the primary regulatory frameworks for understanding what validated analytical procedures can and cannot confirm for peptide identity, purity and impurity profiling. Both documents are publicly available through the ICH website and should be read alongside any CoA before a batch enters a laboratory workflow.
To review batch documentation for specific research peptides, browse Veyvora’s research-peptide catalogue and use the lot-number search to retrieve the CoA for your material.
